Evidence map›Paper›PMID 37266188›Full record

ReviewCurrent addiction reports2023

Clinical Implications of Kratom (

Elisabeth Prevete, Kim Paula Colette Kuypers, Eef Lien Theunissen, Gianluca Esposito, Johannes Gerardus Ramaekers, Massimo Pasquini, Ornella Corazza

Abstract readReview
In one paragraph

Review in Current addiction reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Atypical respiration patterns of kratom alkaloids.The Journal of pharmacology and experimental therapeutics · 2026
    Article
  3. Article
  4. Kratom Brands in Vape Shops Across the US.Health behavior research · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Journal of Taibah University Medical Sciences · 2024
    Review
  11. Review
  12. Review
  13. Spray film-forming system formulation ofJournal of advanced pharmaceutical technology & research
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elisabeth PreveteDepartment of Human Neurosciences, Sapienza University of Rome, Viale Dell'Università 30, 00185 Rome, Italy.ORCID 0000-0002-8053-7662
Kim Paula Colette KuypersDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, P.O. Box 616, 6200 MD Maastricht, the Netherlands.
Eef Lien TheunissenDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, P.O. Box 616, 6200 MD Maastricht, the Netherlands.
Gianluca EspositoDepartment of Psychology and Cognitive Science, University of Trento, Corso Bettini, 84, 38068 Rovereto, Italy.
Johannes Gerardus RamaekersDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, P.O. Box 616, 6200 MD Maastricht, the Netherlands.
Massimo PasquiniDepartment of Human Neurosciences, Sapienza University of Rome, Viale Dell'Università 30, 00185 Rome, Italy.
Ornella CorazzaDepartment of Psychology and Cognitive Science, University of Trento, Corso Bettini, 84, 38068 Rovereto, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose of Review: This work aims to provide an up-to-date review of the preclinical and clinical scientific literature on the therapeutic value of kratom to better understand the underlying mechanisms related to its use and inform future therapeutic applications. Recent Findings: A growing number of studies, mainly of cross-sectional nature, describe the widespread use of kratom by individuals to self-treat pain, psychiatric symptoms, and substance use disorders (SUD) outside a controlled clinical setting. Preclinical evidence suggests kratom is effective as an analgesic agent and might decrease the self-administration of other drugs. A randomized controlled trial has further supported kratom's therapeutic value as an analgesic. Investigations in nonclinical samples of long-term kratom users also indicate its therapeutic benefit in managing SUD symptoms (e.g., craving) and long-term or acute symptoms (e.g., withdrawal) for alcohol, opioids, and other illicit drugs. However, episodes of kratom-related intoxications have also been reported, often due to the adulteration and the contamination of kratom products mainly sold online or mixed toxicities when consumed outside clinical and traditional settings. Summary: Evidence on the clinical implications of kratom use is still limited and uncertain, with kratom research constantly evolving. Therefore, further randomized trials are needed.

Indexed as

Adverse effectsClinical implicationsKratomMitragyna speciosaMitragynineTherapeutic use

Identifiers

PMID37266188
PMCPMC10177737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.